Introduction
Lung cancer, the most common type of cancer and the leading cause of cancer-related deaths worldwide, remains a great threat to public health across the world. 1 Each year, >1 million new cases are diagnosed with lung cancer, and over 1 million deaths are attributed to this malignancy. 2 As a major type of lung cancer, non-small-cell lung cancer (NSCLC) accounts for ~85% of all lung cancers. 3 Metastasis determines the design of the treatment regimen and prognosis in NSCLC patients. 4, 5 Brain is a common metastatic site in patients with NSCLC, and ~20%-25% of the NSCLC patients at initial diagnosis are estimated to have brain metastasis. 6, 7 It has been shown that the NSCLC patients with brain metastases have a poor prognosis, low quality of life, and short survival, with a median survival period of only 1-2 months in untreated patients. [8] [9] [10] [11] Currently, the treatment options for NSCLC with brain metastasis mainly include stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), surgery, chemotherapy, targeted therapy, and symptomatic and supportive treatment. [12] [13] [14] WBRT and SRS remain the standard treatment for brain metastases in NSCLC; however, such treatments exhibit limited effects on patients' survival, which only prolong the survival period of 4-6 months. 15, 16 Conventional therapies, such as chemotherapy, have shown an unsatisfactory efficacy in the treatment of brain metastases in NSCLC due to the presence of blood-brain barrier (BBB). 17 A search for treatments that may greatly prolong the survival and improve the prognosis has, therefore, been paid much attention in NSCLC patients with brain metastases.
Driver gene-targeted therapy achieves better survival benefits for the patients with advanced NSCLC, and EGFR is a predominant driver oncogene in NSCLC. 18 EGFR-tyrosine kinase inhibitors (TKIs) have been accepted as the initial therapy for advanced NSCLC patients with EGFR-sensitive mutations, and EGFR-TKI treatment was reported to achieve an overall response rate (ORR) of 55%-85%, progressionfree survival (PFS) of ~12 months, and overall survival (OS) of 24-36 months in advanced EGFR-mutant NSCLC patients. [19] [20] [21] Data from Phase 3 clinical trials have shown that EGFR-TKI treatment may increase the objective response rate (RR), prolong the PFS, and cause significantly lower incidence of adverse reactions in NSCLC patients relative to in platinum-containing double-drug chemotherapy. 22, 23 It has been found that the NSCLC patients harboring an EGFR mutation have a higher incidence of brain metastasis (30%-70%) than those without EGFR mutations, and the management of brain metastasis is, therefore, critical to antitumor therapy in NSCLC patients harboring an EGFR mutation. [24] [25] [26] [27] Data from clinical trials have demonstrated that EGFR-TKIs may cause regression of established brain metastases from NSCLC, with an intracranial RR of 75% in treatment-naïve, advanced EGFR-mutant NSCLC patients. [28] [29] [30] To date, the optimal timing of brain radiotherapy, however, remains controversial in EGFR-mutant lung cancer patients with brain metastasis in the presence of well-controlled intracranial and extracranial lesions by EGFR-TKIs. The present study was, therefore, designed to compare the efficacy of concurrent EGFR-TKIs and WBRT vs EGFR-TKI alone in a retrospective cohort of advanced EGFR-mutant NSCLS with brain metastases, so as to provide insights into the optimal timing of brain radiotherapy.
Patients and methods

Study subjects
The medical records of 104 treatment-naïve, advanced EGFR-mutant NSCLC patients with brain metastases admitted to Fujian Provincial Cancer Hospital (Fuzhou, People's Republic of China) during the period from January 1, 2012 to June 30, 2017 were retrospectively reviewed. All NSCLCs were definitively diagnosed with pathologic examinations, and EGFR mutation analysis was performed using amplification refractory mutation system PCR or next-generation sequencing. There were 56 patients undergoing concurrent EGFR-TKI and WBRT, and 48 patients given EGFR-TKI alone, including 20 cases with salvage WBRT upon brain metastasis progression.
Treatment regimens
All patients received an initial MRI scan of the brain prior to administration of EGFR-TKIs and every 2-3 months posttreatment with EGFR-TKIs. All subjects were given 150 mg erlotinib (Roche, Basel, Switzerland) once a day (QD), 250 mg gefitinib (AstraZeneca Pharmaceuticals, Waltham, MA, USA) QD or 150 mg icotinib (Betta Pharmaceuticals Co., Ltd., Hangzhou, People's Republic of China) three times a day, and WBRT was delivered at a dose of 30 Gy divided in ten fractions for 5 days a week, given at a total of 2 weeks. The response to therapy was evaluated according to the Response Evaluation Criteria in Solid Tumor version 1.1, 1 month after the initial treatment with EGFR-TKIs, 31 followed by once every 2-3 months, and the adverse events were assessed according to the Common Terminology Criteria for Adverse Events version 4.0. 
Survival analysis
Intracranial PFS (iPFS) was defined as the survival from initial EGFR-TKIs treatment to intracranial progression following WBRT. OS was estimated from the date of initial diagnosis until the date of death or the last follow-up.
Statistical analysis
All data were entered into Microsoft Excel 2007 (Microsoft, Inc., Redmond, WA, USA), and all statistical analyses were performed using the statistical software SPSS version 23.0 (IBM Corporation, Armonk, NY, USA). Chi-squared test or Fisher's exact test was used to compare the clinicopathologic characteristics between the two cohorts. Survival curves were generated using the Kaplan-Meier method, and the survival probability was compared with the log-rank test. A Cox regression model was employed for univariate and multivariate analyses to evaluate the corresponding 95% CIs and HRs. A P value of <0.05 was considered statistically significant.
informed consent
All participants signed the informed consent pertaining to targeted therapy or brain radiotherapy. All subjects involved in this study agreed to publish related demographic and clinical features.
ethical approval
The study protocol was reviewed and approved by the Ethical Review Committee of Fujian Provincial Cancer Hospital (approval no. FJZLYY2015-00179). All experimentations described in this study were conducted in accordance with the Declaration of Helsinki.
Results
Clinicopathologic characteristics of the study subjects
The study subjects included 45 men and 59 women, and had a median age of 59 years (range, 23-79 years) at diagnosis. Of all subjects, 97.1% were diagnosed with adenocarcinoma and 88.5% had an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. There were 83 cases with extracranial metastases and 48 cases with symptomatic brain metastases initially. In addition, there were 39 cases harboring an EGFR exon 19 deletion mutation, 39 cases harboring an EGFR exon 21L858R mutation, 5 cases harboring an EGFR exon 21L861Q mutation, 4 cases harboring an EGFR exon 18G719X mutation, 4 cases harboring combined EGFR exon 21L858R and exon 20 T790M mutations, 4 cases harboring combined EGFR exon 19 deletion mutation and exon 20 T790M mutation, while the mutation sites of the other 9 cases were unclear. The baseline clinicopathologic features were balanced between the two cohorts (Table 1) .
intracranial progression
The subjects received follow-up for a median period of 23 months (range, 5-82 months). At the end of the follow-up period (June 30, 2017), 36 subjects remained alive and 66 cases were dead due to disease progression. Of all subjects, 86 cases (82.7%) had an intracranial progressive disease, with a median iPFS of 14.5 months (95% CI, 11.924-17.076 months). Intracranial progression developed in 76.8% (43/56) of the patients receiving EGFR-TKIs plus and WBRT, while intracranial progression occurred in 89.6% (43/48) of the cases given EGFR-TKIs alone. The median iPFS was 17.7 months (95% CI, 16.288-22.212 months) in the patients receiving concurrent EGFR-TKIs and WBRT, which was significantly longer than that of those given EGFR-TKIs alone (median iPFS, 11.0 months; 95% CI, 8.067-13.933 months; P=0.015), as shown in Table 2 and Figure 1 .
The 70 patients with more than three brain metastases had a median iPFS of 12.5 months (95% CI, 12.952-17.432 months), which was significantly shorter than that of 34 cases with three or less brain metastases (median iPFS, 18.0 months; 95% CI, 16.142-23.554 months; P=0.044), as shown in Figure 2 .
Among the study subjects, there were 6 patients (5.8%) with complete response and 42 patients (40.4%) with partial response, yielding an ORR of 46.2%. In addition, there were 52 patients (50.0%) with stable disease. The ORR was comparable between the patients receiving concurrent EGFRTKIs and WBRT and EGFR-TKIs alone (48.2% vs 54.2%, P=0.562; Table 3 ). Cox multivariate regression analysis revealed that concurrent EGFR-TKIs and WBRT was an independent predictor of iPFS (P=0.004) and more than three brain metastases was a potential independent predictor unfavorably affecting iPFS in advanced EGFR-mutant NSCLC patients (P=0.017; Table 4 ).
Survival outcomes
Thirty-six patients survived until the end of the followup period. Among all study subjects, the median OS was 27.3 months (95% CI, 23.109-31.491 months), and no significant difference was found in the median OS between the patients receiving concurrent EGFR-TKIs and WBRT (median OS, 28 Figure 3 ).
Subgroup analyses
Subgroup analyses revealed that of the 70 patients with more than three brain metastases, the median iPFS was significantly longer in cases receiving concurrent EGFR-TKIs and WBRT (median iPFS, 17.6 months; 95% CI, 14.176-21.024 months) than in those given EGFR-TKIs alone (median iPFS, 9.2 months; 95% CI, 6.924-11.476 months; P=0.001), as shown in Figure 4 . Among the 34 patients with three or less brain metastases, however, no significant difference was detected in the median iPFS between the patients receiving concurrent EGFR-TKIs and WBRT and EGFR-TKIs alone (P=0.526; Figure 5 ).
Toxicity
During the treatment period, the incidence of adverse events was 85.7% and 83.3% in the subjects receiving concurrent EGFR-TKIs and WBRT and EGFR-TKIs alone. In cases given EGFR-TKIs alone, the incidence of grade 3 and higher adverse events was 2.1%, and in the cases receiving concurrent EGFR-TKIs and WBRT, the incidence of grade 3 and higher adverse events was 8.9%, including a case with reduced drug doses due to the development of grade 3 diarrhea. The WBRT-related adverse events mainly included dizziness and headache, which were alleviated following dehydration treatment, as well as neurocognitive impairment Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group Performance Status; iPFS, intracranial progression-free survival; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.
Figure 1 Kaplan-Meier curves for iPFS in advanced EGFR-mutant NSCLC patients.
Notes:
The median iPFS is significantly longer in patients receiving concurrent EGFRTKIs and WBRT than in those given EGFR-TKIs alone (17.7 vs 11.0 months, P=0.015). Abbreviations: iPFS, intracranial progression-free survival; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy. (grade 1 and 2 in three cases and grade 3 in one case), as shown in Table 5 .
Discussion
Currently, the treatment of advanced NSCLC with brain metastasis remains a great challenge, [8] [9] [10] and EGFR-mutant NSCLC has been found to be more likely to present brain metastases. [24] [25] [26] [27] Prior to the introduction of EGFR-TKI, WBRT, surgical resection of the metastatic lesions, and SRS were the standard treatments of brain metastasis; however, radiotherapy and surgery cause non-ignorable brain damages, which may seriously affect patients' survival and quality of life.
12-16 EGFR-TKI is an emerging effective treatment option for EGFR-mutant lung cancer patients with brain metastasis. 33 Results from the CTONG-0803 Phase 2 clinical trial showed that the single-agent erlotinib at a daily dose of 150 mg was active and well tolerated as a second-line therapy in NSCLC patients with brain metastasis, which achieved 10.1 months iPFS. 34 efficacy of icotinib vs whole-brain irradiation with or without chemotherapy revealed that icotinib treatment (median iPFS, 10.1 months) achieved significantly longer iPFS than WBI plus chemotherapy (median iPFS, 4.8 months) in patients with EGFR-mutant NSCLC and multiple brain metastases. 35 Since brain radiotherapy may cause brain injuries, the optimal timing of brain radiotherapy remains in dispute until now. In EGFR-mutant NSCLC patients with brain metastasis, is the first-line brain radiotherapy is required? Does brain radiotherapy serve as a salvage therapy upon intracranial tumor progression? These questions remain to be answered. Previous studies have shown that concurrent EGFR-TKI and brain radiotherapy (WBRT or SRS) may increase the intracranial disease control rate and extend the OS in EGFR-mutant NSCLC patients. [36] [37] [38] In addition, a recent multi-institutional analysis demonstrated that SRS followed by EGFR-TKI resulted in the longest OS and allowed patients to avoid the potential neurocognitive sequelae of WBRT in EGFR-mutant NSCLC patients with brain metastases. 39 Our data showed that concurrent EGFR-TKIs and WBRT achieved significantly longer iPFS than EGFR-TKIs alone (median iPFS, 17.7 vs 11.0 months, P=0.015), which was similar to a previous study reporting that concurrent early brain radiotherapy with EGFR-TKI may improve intracranial disease control in EGFR-mutant NSCLC with brain metastasis. 38 Results from a Phase 2 clinical trial showed that erlotinib in combination with WBRT was well tolerated with a favorable objective RR in patients with brain metastases from NSCLC. 40 Due to the protection of the BBB, the drug concentration is not high in the central nervous system (CNS). 41 Therefore, optimal CNS penetration is a critical issue for patients with brain metastases. 42 Brain radiotherapy is found to destroy the BBB and increase the TKIs concentration in the cerebrospinal fluid. 43, 44 In addition, it has been shown that EGFR mutation is a radiosensitive NSCLC genotype Abbreviations: iPFS, intracranial progression-free survival; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy. and EGFR-TKI is supposed to be a radiosensitizer. 43, 45, 46 It is, therefore, hypothesized that EGFR-TKI and WBRT may have a synergistic effect, and the combination of EGFR-TKI and WBRT may result in better intracranial tumor control in NSCLC harboring EGFR mutations. Taking these findings together, it is considered that concurrent EGFR-TKIs with WBRT may achieve better intracranial tumor control in NSCLC harboring EGFR mutations.
In the current study, concurrent EGFR-TKIs with WBRT (median OS, 28.1 months) achieved extension of the OS relative to EGFR-TKIs alone (median OS, 24 months), although no significant difference was seen between these two regimens in terms of the median OS (P=0.756). Of the 48 patients initially treated with EGFR-TKI alone, there were 20 cases receiving salvage WBRT upon brain metastasis progression, and 58.3% of the cases lost the timing for WBRT due to physical intolerance and treatment abandonment. Our data showed no significant difference in the OS between the patients receiving concurrent EGFR-TKIs with WBRT and EGFR-TKIs alone. Follow-up revealed that the majority of the patients were well tolerant to WBRT, with only a case developing grade 3 neurocognitive impairment, Abbreviations: iPFS, intracranial progression-free survival; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy. We, therefore, recommend concurrent EGFR-TKI with brain radiotherapy as an initial therapy for EGFR-mutant NSCLC patients with brain metastasis. A retrospective multi-institutional analysis showed that SRS followed by EGFR-TKI (46 months) achieved longer median OS than WBRT followed by EGFR-TKI (30 months) and EGFR-TKI followed by SRS or WBRT (25 months) at intracranial progression in EGFR-mutant NSCLC patients with brain metastases (P<0.001). 39 In addition, SRS was found to have less toxicity and avoided the potential neurocognitive sequelae from WBRT. 47, 48 EGFR-TKI plus brain radiotherapy, notably SRS, as an initial therapy, may improve the survival and avoid losing the timing for radiotherapy, which may be an optimal option for the treatment of EGFR-mutant NSCLC with brain metastasis. However, a prospective, randomized clinical trial is urgently needed to confirm the findings.
In this study, a Cox multivariate regression analysis revealed that the number of brain metastasis was an independent predictor of iPFS, and advanced EGFR-mutant NSCLC patients with three or less brain metastases at initial diagnosis affected iPFS favorably. Previous studies have demonstrated that ECOG performance status, EGFR mutation subtype, and absence of extracranial metastases are independent predictors of iPFS and OS in NSCLC patients with brain metastasis, 39, 49 which was not found in the present study. Our data report a single-institution experience and the study sample is small. Further large-scale, multicenter, retrospective studies to identify the factors affecting iPFS and OS in NSCLC patients with brain metastasis are warranted.
Currently, neurosurgery or radiosurgery is the standard option for the radical therapy of locally intracranial metastatic tumors, and SRS is accepted as the first choice for the local treatment of locally intracranial metastatic tumors. 50, 51 However, either surgery or radiotherapy is invasive and has side effects, while EGFR-TKI shows a high response and few adverse effects for intracranial metastatic tumors. 50, 51 To defer or avoid neurocognitive sequelae from WBRT, it is necessary to identify the patient population given EGFR-TKI alone as the initial therapy. Our subgroup analysis showed that concurrent EGFR-TKI and WBRT improved median iPFS compared with EGFR-TKI alone in patients with more than three brain metastases (P=0.001); however, no significant difference was observed between the two regimens in patients with three or less brain metastases (P=0.526). It is hypothesized that, in EGFR-mutant NSCLC with three or less brain metastases, EGFR-TKI alone may be an option as a first-line therapy; however, this requires further investigations to test such a hypothesis. Osimertinib, an oral, CNS-active, third-generation EGFR-TKI, was found to be effective in crossing the BBB and penetrating the CNS. 52 Data from the FLAURA study revealed that osimertinib achieved a significantly higher CNS objective RR (66%) than the firstgeneration EGFR-TKI and remarkably reduced the risk of intracranial progression in advanced NSCLC patients with EGFR-TKI-sensitizing mutation. 53 In Asian patients with previously untreated advanced NSCLC harboring exon 19 deletion (Ex19del)/L858R EGFR-TKI-sensitizing mutations, first-line osimertinib demonstrated a clinically meaningful improvement in PFS over the standard of care EGFR-TKI (gefitinib or erlotinib) (median PFS, 16.5 vs 11.0 months, HR =0.54, 95% CI, 0.41-0.72; P<0.0001). 54 However, more investigations are required to demonstrate the likelihood of osimertinib as an alternative of brain radiotherapy in EGFRmutant, advanced NSCLC patients with brain metastases. In addition, prospective studies are needed to identify the patient population given EGFR-TKI alone in whom brain radiotherapy is not needed, in order to protect them against radiation-induced neurocognitive sequelae from WBRT.
Conclusion
The results of the present study demonstrate that concurrent EGFR-TKI and WBRT may improve intracranial disease control in advanced EGFR-mutant NSCLC with brain metastasis. Initial treatment with EGFR-TKI alone may cause a loss of timing for WBRT, and concurrent EGFR-TKI with WBRT may be an optimal option for EGFR-mutant NSCLC with brain metastasis at the initial diagnosis. However, EGFR-TKI alone may be an option as the first-line therapy in patients with three or less brain metastases, which may defer or avoid neurocognitive sequelae from WBRT. Further multi-institutional, prospective, randomized clinical trials to validate our findings and determine the optimal treatment for EGFR-mutant NSCLC with brain metastasis seem justified.
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